Biogen Idec and Biovitrum AB have announced plans to advance the long-acting, fully recombinant Factor IX Fc fusion protein (rFIXFc) towards registrational clinical trials in haemophilia B patients.
Haemophilia B requires frequent injections, creating a significant burden for the majority of individuals with the disorder. This registration trial will evaluate the potential of the treatment to prolong protection from bleeding and reduce the frequency of injections.
Go deeper with GlobalData
The decision to advance the programme is based on promising data from a Phase I/IIa safety dose-escalation and pharmacokinetic study of intravenous rFIXFc in severe, previously-treated haemophilia B patients.
During the study rFIXFc was well tolerated and demonstrated a prolonged half-life compared to historical data for existing therapies, supporting advancement of the programme.
Biovitrum CEO Martin Nicklasson said that the Phase I/II results are very encouraging.
“The decision to initiate our first registrational programme represents true progress in our efforts to offer haemophilia B patients treatment that makes a significant difference,” Nicklasson said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe trial will begin following approval from relevant regulatory authorities. rFIXFc has already received orphan medicinal product designation for the treatment of haemophilia B from the European and US authorities.
